XML 28 R17.htm IDEA: XBRL DOCUMENT v3.5.0.2
Segment Reporting
 9 Months Ended
Sep. 30, 2016
Segment Reporting [Abstract]  
SEGMENT REPORTING
SEGMENT REPORTING

In 2016 and 2015, we identified six operating segments including Interventional Cardiology, Peripheral Interventions, Rhythm Management, Endoscopy, Urology and Pelvic Health, and Neuromodulation. Our reportable segments represent an aggregate of operating segments based on the criteria prescribed in FASB ASC Topic 280, Segment Reporting. We have three reportable segments comprised of Cardiovascular, Rhythm Management, and MedSurg. Each of our reportable segments generates revenues from the sale of medical devices. We measure and evaluate our reportable segments based on segment net sales and operating income, excluding the impact of changes in foreign currency. Sales generated from reportable segments, as well as operating results of reportable segments, are based on internally-derived standard currency exchange rates, which may differ from year to year, and do not include intersegment profits. As needed, we restate segment information for the prior period based on our internally-derived standard currency exchange rates used for the current period in order to remove the impact of foreign currency exchange fluctuation. We exclude from segment operating income certain corporate-related expenses and certain charges or credits that our chief operating decision maker considers to be non-recurring and/or non-operational, such as amounts related to intangible asset impairment charges; acquisition-, litigation-, restructuring- and restructuring-related net charges and credits; debt extinguishment charges; pension termination charges; and amortization expense. Although we exclude these amounts from segment operating income, they are included in reported consolidated operating income (loss) and are included in the reconciliation below.

A reconciliation of the totals reported for the reportable segments to the applicable line items in our accompanying unaudited condensed consolidated statements of operations is as follows:
 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
(in millions)
 
2016
 
2015
 
2016
 
2015
 
 
 
 
 
 
 
 
 
Net sales
 
 
 
 
 
 
 
 
Interventional Cardiology
 
$
620

 
$
551

 
$
1,870

 
$
1,659

Peripheral Interventions
 
273

 
246

 
815

 
723

Cardiovascular
 
893

 
797

 
2,685

 
2,382

 
 
 
 
 
 
 
 
 
Cardiac Rhythm Management
 
498

 
483

 
1,481

 
1,456

Electrophysiology
 
64

 
61

 
192

 
182

Rhythm Management
 
562

 
544

 
1,673

 
1,638

 
 
 
 
 
 
 
 
 
Endoscopy
 
393

 
362

 
1,148

 
1,042

Urology and Pelvic Health
 
260

 
207

 
773

 
479

Neuromodulation
 
143

 
128

 
407

 
369

MedSurg
 
796

 
697

 
2,328

 
1,890

Net sales allocated to reportable segments
 
2,251

 
2,038

 
6,686

 
5,910

Impact of foreign currency fluctuations
 
(146
)
 
(150
)
 
(491
)
 
(411
)
 
 
$
2,105

 
$
1,888

 
$
6,195

 
$
5,499

 
 
 
 
 
 
 
 
 
Income (loss) before income taxes
 
 
 
 
 
 
 
 
Cardiovascular
 
$
292

 
$
249

 
$
885

 
$
732

Rhythm Management
 
113

 
97

 
300

 
252

MedSurg
 
262

 
235

 
763

 
590

Operating income allocated to reportable segments
 
667

 
581

 
1,948

 
1,574

Corporate expenses and currency exchange
 
(156
)
 
(145
)
 
(446
)
 
(334
)
Intangible asset impairment charges; acquisition-related net charges and credits; restructuring- and restructuring-related net charges; litigation-related net charges and credits; and pension termination charges
 
(27
)
 
(604
)
 
(787
)
 
(935
)
Amortization expense
 
(136
)
 
(131
)
 
(408
)
 
(361
)
Operating income (loss)
 
348

 
(299
)
 
307

 
(56
)
Other expense, net
 
(91
)
 
(68
)
 
(219
)
 
(256
)
Income (loss) before income taxes
 
$
257

 
$
(367
)
 
$
88

 
$
(312
)